Acoramidis provides consistent clinical benefit in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) irrespective of baseline atrial fibrillation (AF) status, according to a post hoc analysis of the ATTRibute-CM trial (NCT03860935) published in the Journal of Cardiac Failure.
A team of researchers evaluated outcomes by baseline AF status among 611 participants with ATTR-CM randomized 2:1 to acoramidis or placebo for 30 months. They noted that AF affected 68.7% of the trial population at baseline, with these individuals tending to have more advanced disease than their non-AF counterparts.
Compared with the placebo, acoramidis reduced the risk of all-cause mortality or first cardiovascular-related hospitalization regardless of baseline AF status, with no significant interaction between AF status and treatment effect.